热门资讯> 正文
Foghorn Therapeutics任命Ryan Maynard为首席财务官
2026-02-23 20:27
- Foghorn Therapeutics (FHTX) said on Monday that Ryan Maynard will join the clinical-stage biotech as CFO effective Feb. 23, 2026.
- Maynard brings over 25 years of executive experience in biopharma and healthcare technology, has raised more than $1 billion in public and private financings, and most recently served as CFO of Cara Therapeutics. He currently serves on the board of Iovance Biotherapeutics.
- Shares -1.72%.
More on Foghorn Therapeutics
- Seeking Alpha’s Quant Rating on Foghorn Therapeutics
- Historical earnings data for Foghorn Therapeutics
- Financial information for Foghorn Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
